It's behind a paywall, but the gist is that some of these patients had TB resistant to ALL of the following:
isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin (1st-line agents); as well as ofloxacin, moxifloxacin, kanamycin, amikacin, capreomycin, para-aminosalicylic acid, and ethionamide (apparently 2nd-line agents).
Interestingly, the report doesn't discuss whether experimental/3rd-line treatments were tried (including my favorite from M2 year, linezolid). So it's possible that there's still something in our armamentarium that hasn't yet been tried (due, perhaps, to prohibitive cost). (And note that TB, and ID in general, is not my area of focus.)